Literature DB >> 17888748

Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization.

S M Nordstrom1, S M Carleton, W L Carson, M Eren, C L Phillips, D E Vaughan.   

Abstract

The plasminogen activation system (PAS) and its principal inhibitor, plasminogen activator inhibitor-1 (PAI-1), are recognized modulators of matrix. In addition, the PAS has previously been implicated in the regulation of bone homeostasis. Our objective was to study the influence of active PAI-1 on geometric, biomechanical, and mineral characteristics of bone using transgenic mice that over-express a variant of human PAI-1 that exhibits enhanced functional stability. Femora were isolated from male and female, wildtype (WT) and transgenic (PAI-1.stab) mice at 16 and 32 weeks of age (n=10). Femora were imaged via DEXA for BMD and muCT for cortical mid-slice geometry. Torsional testing was employed for biomechanical properties. Mineral composition was analyzed via instrumental neutron activation analysis. Female femora were further analyzed for trabecular bone histomorphometry (n=11). Whole animal DEXA scans were performed on PAI-1.stab females and additional transgenic lines in which the functional domains of the PAI-1 protein were specifically disrupted. Thirty-two week female PAI-1.stab femora exhibited decreased mid-slice diameters and reduced polar moment of area compared to WT, while maintaining similar cortical bone width. Greater biomechanical strength and stiffness were demonstrated by 32 week PAI-1.stab female femora in addition to a 52% increase in BMD. PAI-1.stab trabecular bone architecture was comparable to WT. Osteoid area was decreased in PAI-1.stab mice while mineral apposition rate increased by 78% over WT. Transgenic mice expressing a reactive-site mutant form of PAI-1 showed an increase in BMD similar to PAI-1.stab, whereas transgenic mice expressing a PAI-1 with reduced affinity for vitronectin were comparable to WT. Over-expression of PAI-1 resulted in increased mineralization and biomechanical properties of mouse femora in an age-dependent and gender-specific manner. Changes in mineral preceded increases in strength/stiffness and deterred normal cross-sectional expansion of cortical bone in females. Trabecular bone was not altered in PAI-1.stab mice whereas MAR increased significantly, further supporting mineral changes as the underlying factor in strength differences. The primary influence of PAI-1 occurred during a period of basal bone remodeling, attributing a role for this system in remodeling as opposed to development. Comparison of transgenic lines indicates that PAI-1's influence on bone is dependent on its ability to bind vitronectin, and not on its proteolytic activity. The impact of PAI-1 on mouse femora supports a regulatory role of the plasminogen activation system in bone homeostasis, potentially elucidating novel targets for the treatment of bone disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17888748      PMCID: PMC3933377          DOI: 10.1016/j.bone.2007.08.020

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  63 in total

Review 1.  Interleukin-6: An osteotropic factor influencing bone formation?

Authors:  Nathalie Franchimont; Sylvie Wertz; Michel Malaise
Journal:  Bone       Date:  2005-08-19       Impact factor: 4.398

Review 2.  The plasminogen activator/plasmin system.

Authors:  J D Vassalli; A P Sappino; D Belin
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

3.  The role of the plasminogen system in bone resorption in vitro.

Authors:  E Daci; N Udagawa; T J Martin; R Bouillon; G Carmeliet
Journal:  J Bone Miner Res       Date:  1999-06       Impact factor: 6.741

4.  The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury.

Authors:  R Renckens; J J T H Roelofs; V de Waard; S Florquin; H R Lijnen; P Carmeliet; T van der Poll
Journal:  J Thromb Haemost       Date:  2005-05       Impact factor: 5.824

Review 5.  Latent transforming growth factor-beta: structural features and mechanisms of activation.

Authors:  J S Munger; J G Harpel; P E Gleizes; R Mazzieri; I Nunes; D B Rifkin
Journal:  Kidney Int       Date:  1997-05       Impact factor: 10.612

6.  Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity.

Authors:  I Shimomura; T Funahashi; M Takahashi; K Maeda; K Kotani; T Nakamura; S Yamashita; M Miura; Y Fukuda; K Takemura; K Tokunaga; Y Matsuzawa
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

Review 7.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

8.  High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

Authors:  A M Thögersen; J H Jansson; K Boman; T K Nilsson; L Weinehall; F Huhtasaari; G Hallmans
Journal:  Circulation       Date:  1998-11-24       Impact factor: 29.690

9.  Increased bone formation in mice lacking plasminogen activators.

Authors:  E Daci; V Everts; S Torrekens; E Van Herck; W Tigchelaar-Gutterr; R Bouillon; G Carmeliet
Journal:  J Bone Miner Res       Date:  2003-07       Impact factor: 6.741

10.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

View more
  12 in total

1.  High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling.

Authors:  Jan K Jensen; Peter G W Gettins
Journal:  Protein Sci       Date:  2008-08-25       Impact factor: 6.725

Review 2.  Molecular genetic studies of gene identification for osteoporosis: the 2009 update.

Authors:  Xiang-Hong Xu; Shan-Shan Dong; Yan Guo; Tie-Lin Yang; Shu-Feng Lei; Christopher J Papasian; Ming Zhao; Hong-Wen Deng
Journal:  Endocr Rev       Date:  2010-03-31       Impact factor: 19.871

3.  Recombinant Human Plasminogen Activator Inhibitor-1 Promotes Cementogenic Differentiation of Human Periodontal Ligament Stem Cells.

Authors:  Hexiu Jin; Han-Wool Choung; Ki-Taek Lim; Bin Jin; Chengbiao Jin; Jong-Hoon Chung; Pill-Hoon Choung
Journal:  Tissue Eng Part A       Date:  2015-08-14       Impact factor: 3.845

4.  Effects of diet-induced obesity and voluntary wheel running on the microstructure of the murine distal femur.

Authors:  Hongqiang Ma; Tuomas Turpeinen; Mika Silvennoinen; Sira Torvinen; Rita Rinnankoski-Tuikka; Heikki Kainulainen; Jussi Timonen; Urho M Kujala; Paavo Rahkila; Harri Suominen
Journal:  Nutr Metab (Lond)       Date:  2011-01-17       Impact factor: 4.169

5.  Systemic transplantation of human adipose-derived stem cells stimulates bone repair by promoting osteoblast and osteoclast function.

Authors:  Kyunghee Lee; Hyunsoo Kim; Jin-Man Kim; Jae-Ryong Kim; Keuk-Jun Kim; Yong-Jin Kim; Se-Il Park; Jae-Ho Jeong; Young-mi Moon; Hyun-Sook Lim; Dong-Won Bae; Joseph Kwon; Chang-Yong Ko; Han-Sung Kim; Hong-In Shin; Daewon Jeong
Journal:  J Cell Mol Med       Date:  2011-10       Impact factor: 5.310

6.  Transgenic overexpression of a stable Plasminogen Activator Inhibitor-1 variant.

Authors:  Abigail T Fahim; He Wang; Jining Feng; David Ginsburg
Journal:  Thromb Res       Date:  2008-09-05       Impact factor: 3.944

7.  Trps1 transcription factor represses phosphate-induced expression of SerpinB2 in osteogenic cells.

Authors:  Mairobys Socorro; Apurva Shinde; Hajime Yamazaki; Sana Khalid; Daisy Monier; Elia Beniash; Dobrawa Napierala
Journal:  Bone       Date:  2020-10-03       Impact factor: 4.398

8.  Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women.

Authors:  Merih Ozgen; Didem Turgut Cosan; Fulya Doganer; Ahu Soyocak; Onur Armagan; Hasan Veysi Gunes; Irfan Degirmenci; Gulsah Ogutler Ozkara; Fezan Sahin Mutlu
Journal:  Clinics (Sao Paulo)       Date:  2012-11       Impact factor: 2.365

9.  Gastric expression of plasminogen activator inhibitor (PAI)-1 is associated with hyperphagia and obesity in mice.

Authors:  Susan Kenny; Joanne Gamble; Suzanne Lyons; Nikolina Vlatkovic; Rod Dimaline; Andrea Varro; Graham J Dockray
Journal:  Endocrinology       Date:  2012-12-18       Impact factor: 4.736

10.  Plasminogen activator inhibitor-1 concentrations and bone mineral density in postmenopausal women with type 2 diabetes mellitus.

Authors:  Silvija Canecki-Varžić; Ivana Prpić-Križevac; Ines Bilić-Ćurčić
Journal:  BMC Endocr Disord       Date:  2016-03-03       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.